17,261 trials
Immune Thrombocytopenia
Primary: Part A: Percentage of Participants Who Achieved 2 or More Consecutive Platelet Counts by Starting Dose Level and Overall — 44.4; 0.0; 40.0; 40.0 percentage of participants
Age-Related Macular Degeneration
Primary: Percentage of Subjects Converting to Exudative AMD at 24 Months. — 6; 7 Participants
Autism Spectrum Disorder
Primary: Pervasive Developmental Disorder Behavior Inventory (PDDBI) - Autism Composite — 115.5; 106.5; 98.1; 91.4 raw score on a scale
Alopecia, Androgenetic
Primary: Non-vellus Target Area Hair Count (TAHC) — 20.3; 22.4; 14.0 hair count
Oral Cavity SCC
Primary: Objective Response Rate Using Pathological Response — 4 Participants
Psoriasis
Primary: Percentage of Participants With a 75% or Greater Psoriasis Area and Severity Index (PASI) Score Reduction From Baseline (PASI75) at Week 12 — 20.0; 44.0; 50.0; 58.3…
B-Cell Acute Lymphoblastic Leukemia, Adult
Primary: Best Overall Response Rate (ORR) — 6; 0; 1; 0 Participants
Cough · Idiopathic Pulmonary Fibrosis
Primary: Mean Change From Baseline in Weekly Average of the Daily Idiopathic Pulmonary Fibrosis Coughing Severity Scale (IPF CSS) — -0.69; -0.66; -0.26; -0.85 Points — p=0.989
Sleep Disturbances Associated With Menopause
Primary: Change From Baseline in Wakefulness After Sleep Onset (WASO) at Week 4 as Measured by Polysomnography (PSG) — -23.50; -1.01 Minutes
Breast Neoplasms
Primary: Stage 1: Percentage of Participants With Objective Response — 10.0; 10.0; 26.9; 16.7 percentage of participants
Recurrent Non-Small Cell Lung Carcinoma · Stage I Non-Small Cell Lung Cancer · Stage II Non-Small Cell Lung Cancer
Primary: ORR Defined as the Proportion of Patients Whose Best Overall Response (BOR) is Either Complete Response (CR) or Partial Response (PR) According to RECIST 1.1 — 0.083…
COVID-19-Induced Parosmia
Primary: Parosmia Olfactory Dysfunction Outcomes Rating — 9; 9; 14; 11 score on a scale 0-112
Bordetella Pertussis, Whooping Cough
Primary: Geometric Mean Fold Rise (GMFR) of Mucosal Immunogenicity S-IgA Against Whole Cell Extract at Day 29 — 3.8; 3.5; 1.2 Fold Rise
Microsatellite Unstable Colorectal Cancer · Microsatellite Stable Colorectal Cancer · Mismatch Repair Proficient Colorectal Cancer
Primary: Objective Response Rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 Per Investigator Assessment — 40.5; 66.4; 71.1; 3.3 percentage of participants
Congenital Diaphragmatic Hernia · Persistent Pulmonary Hypertension of the Newborn · Hypoxemic Respiratory Failure
Primary: Oxygenation Response — 4.2; 2.6 Change in Oxygenation Index